Inclusion Criteria:

- Patients with endometrial cancer diagnosed on endometrial biopsy or dilatation and
curettage.

- Patients with invasive cervical cancer diagnosed on cervical biopsy or cone biopsy.

- Patients with a performance status of 0, 1, 2, or 3 by the Gynecologic Oncology Group
criteria (Appendix).

- Patients with stage I to ~IIA invasive cervical cancer disease according to the
International Federation of Gynecology and Obstetrics (FIGO) clinical staging
criteria (Appendix).

- Patients with clinical stage I endometrial cancer

- Patients who will undergo surgery to include a hysterectomy, radical hysterectomy
and/or radical trachelectomy and bilateral lymphadenectomy via laparotomy or
laparoscopy

- Patients who have signed an approved informed consent.

Exclusion Criteria:

- Patients with history of prior pelvic or para-aortic lymphadenectomy.

- Patients with stage IIB-IV invasive cervical cancer by FIGO criteria.

- Patients with recurrent endometrial or cervical cancer.

- Patients with prior pelvic radiation.

- Any patient with endometrial or cervical cancer treated with neoadjuvant chemotherapy
and radiation therapy.

- Patients with a performance score of 4 by the Gynecologic Oncology Group criteria or
who are not good surgical candidates (Appendix).

- Patients with grossly infected primary tumors.

- Patients with known allergy to triphenyl-ethane compounds.

- Patients with known deficiency of Glucose-G-Phosphate Dehydrogenase.

- Patients with known Hemolytic Anemia from Pyruvate Kinase and G6PD Deficiencies.

- Severe Renal Disease.